Substances · Cathinone derivatives
MDPHP
- Preferred name
- MDPHP
- IUPAC name
- 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylhexan-1-one
- Parent CAS number (reference)
- 776994-64-0
- Molecular formula
- C17H23NO3
- Molecular weight
- 289.4 g/mol
- InChIKey
- OBLFRFGUZZRECT-UHFFFAOYSA-N
- PubChem
- CID 119057580
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
Methylenedioxypyrrolidinohexiophenone 3 4-MDPHP
Verified Neurochemical & Toxicological Intelligence
MDPHP (3',4'-Methylenedioxy-alpha-pyrrolidinohexiophenone)
Receptor Telemetry & Mechanism of Action
Potent norepinephrine-dopamine reuptake inhibitor (NDRI) and six-carbon homologue of MDPV (and 3,4-methylenedioxy analogue of alpha-PHP). Despite its benzodioxole ring, the bulky pyrrolidine moiety abolishes serotonin affinity: IC50 values measure 8.4–50 nM at DAT and 60–935 nM at NET versus 9,000 nM at SERT. Thus MDPHP lacks MDMA-like serotonergic empathy (even though it cross-reacts on hospital ecstasy immunoassays) and instead delivers intense catecholaminergic stimulation.
Biotransformation & Active Metabolites
Human HRMS studies confirm principal alpha-pyrrolidinophenone metabolic pathways (demethylenation, keto reduction, pyrrolidine ring oxidation). Published clinical toxicology confirms transplacental transfer with fetal blood levels exceeding maternal blood (76 ng/mL vs. 16 ng/mL) in a documented fetal demise case.
Temporal Pharmacokinetics
Powerful, long-tail pyrovalerone stimulant combining intense mental drive, task fixation, ego inflation, and strong libido boost with heavy cardiovascular strain.
- Onset 30–60 minutes oral (5–15 minutes mucosal)
- Peak Window 1.5–3 hours oral (45–90 minutes mucosal)
- Total Window 3–6 hours oral (2–4 hours mucosal)
- Residual / Half-Life 2–16 hours oral (2–36 hours mucosal, with post-binge fatigue lasting 1–4 days); human plasma half-life is unverified.
Active at single-digit to low-double-digit milligrams (TripSit common oral 20–35 mg, KnowDrugs 20–40 mg; mucosal 10–20 mg), with batch potency varying widely. Long-lasting after-effects (2–16 hours oral, up to 36 hours mucosal) mean repeated exposure rapidly causes multi-day sleep deprivation, severe paranoid psychosis, rhabdomyolysis, and documented single-substance fatalities.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
3–5 mg (tentative estimate below 5 mg light floor; mucosal: 2–5 mg)
Crisp wakefulness, heightened vigilance, and subtle mood elevation.
Mild heart-rate increase and appetite suppression.
10–20 mg (KnowDrugs 5–20 mg; mucosal: 5–10 mg)
Strong focus intensification, motivation boost, confidence, and energetic sociability.
Noticeable pulse and blood-pressure rise, dry mouth, and light muscle tension.
20–35 mg (KnowDrugs 20–40 mg; mucosal: 10–20 mg)
Intense dopaminergic mood elevation, pronounced libido increase, ego inflation, rapid thought streams, and urge to redose.
Significant hypertension and tachycardia, vasoconstriction, jaw clenching, frequent urination, and temporary erectile dysfunction.
35–60 mg (mucosal: 20+ mg)
Thought disorganization, hyper-vigilant anxiety, compulsive fixation, mania, and emerging paranoia.
Heavy cardiac pounding, chest pain, muscle cramps, tremors, headaches, and prolonged 16–36 hour insomnia.
60+ mg (or binge repeated exposure)
Severe paranoid psychosis, hallucinations, delusions, and multi-day exhaustion.
Rhabdomyolysis, severe hypertension and tachycardia, chest pain, seizures, and documented fatal single-drug intoxication.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
Nanomolar DAT blockade (IC50 8.4–50 nM) combined with MAO inhibition causes catastrophic hypertensive crisis and cardiac arrest.
Published ICU toxicology confirms severe vasoconstriction, serotonin/sympathomimetic crisis, seizures, and risk of heart failure.
Extreme additive myocardial strain, rhabdomyolysis, hypertension, and convulsions.
Elevated Hazard — Avoid
Masks depressant respiratory risk during peak while worsening cardiac toxicity; strictly contraindicated in pregnancy due to confirmed placental transfer and fetal demise.
High risk of acute manic psychosis, delusions, and erratic behavioral toxicity.
Caution / Receptor Attenuation
Frequently triggers severe paranoia, hallucinations, and tachycardia during MDPHP's long offset.
Intensifies restlessness, muscle tension, and blood-pressure spikes.
Structural Isomer & Sibling Comparison
MDPHP is the 3,4-methylenedioxy analogue of alpha-PHP and one-carbon homologue of MDPV. Compared to alpha-PVP and alpha-PHP, MDPHP has slightly higher milligram brackets (common oral 20–35 mg vs. 10–25 mg) and milder peak intensity than MDPV, yet shares their negligible-serotonin NDRI profile, prolonged 16–36 hour insomnia tail, and high psychosis risk on repeated exposure. Unlike eutylone (which also carries a benzodioxole ring), MDPHP lacks partial SERT release.
Physicochemical Stability & Storage
Physical Form: White to off-white crystalline solid (hydrochloride salt, MW 325.8 g/mol) or fine tan/beige powder. · HCl salt is soluble in PBS (pH 7.2, ~10 mg/mL), ethanol (~1 mg/mL), methanol (~1 mg/mL), and DMSO (~0.5 mg/mL).
Store sealed in an airtight, light-protected container in a cool, dry place.
Cross-Tolerance & Dependence Profile
Very high psychological dependence and binge-addiction liability; cross-tolerant with all dopaminergic stimulants (alpha-PVP, alpha-PHP, alpha-PiHP, NEP, cocaine). Post-binge crash involves 1–4 days of physical fatigue, thought disorganization, back/muscle aches, and vivid nightmares.
Codes on this card
Short meanings for the abbreviations printed with this substance.
DAT
Dopamine transporter
DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.
NET
Norepinephrine transporter
NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.
SERT
Serotonin transporter
SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.
SNDRA / NDRI
Releaser or reuptake blocker
An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.
EC₅₀ / IC₅₀
Halfway concentration
EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.
ratio
Selectivity ratio
A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.
5-HT ↑↑
Serotonergic Overload (Serotonin Toxicity)
A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.
HR / Naczynia
Vasoconstriction & Cardiovascular Load
Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.
Chemical Architecture & Structural Profile
MDPHP (1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-ylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C17H23NO3 and a molar mass of 289.4 g/mol. The parent molecule is indexed under CAS registry number 776994-64-0 and in the NCBI PubChem database as CID 119057580 (Standard InChIKey: OBLFRFGUZZRECT-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), MDPHP is indexed within the Cathinone derivatives structural group. As a substituted beta-ketone (cathinone derivative), this compound requires strict analytical verification and has documented contraindications with MAOIs, serotonergic agents, and other stimulants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Riksdagen — Förordning (1999:58) om förbud mot vissa hälsofarliga varor — Sveriges riksdag (2026-11-12)